The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients
Authors' conclusion
This study shows that patients with ACC have a better prognosis when the disease recurs as a single lesion and supports the use of locoregional treatments to treat disease recurrence.
Study context
- Population
- Patients with postoperative adrenocortical carcinoma (ACC) recurrence, single reference centre
- Participants
- 106 patients
- Exposure
- Recurrence patterns: unique lesion vs multiple lesions in a single organ vs multiple organs
- Outcome
- Survival and recurrence pattern
- Follow-up
- Median 45 months
Methodological detailssingle reference centre
- Single reference centre
Main finding
As reported in the abstract
Months
- Median recurrence-free survival (RFS)
- 12 (IQR 6-23)
- Median overall survival (OS)
- 45 (IQR 29-75)
Observational data: associations, not effects.
Further findings
Locoregional treatment use
Disease-free after treatment of recurrence
- Free of disease
- 60.4%
- Second RFS
- 15 months (IQR 6-64)
Factors associated with mortality
- Margin status RX and R1, % increase in Ki67 and recurrence in multiple organs associated with increased mortality risk; adjuvant mitotane and longer time to first recurrence with reduced risk
- Recurrence in multiple organs and systemic treatment of recurrence negatively affected survival from treatment of recurrence
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. Eur J Endocrinol. Published 19 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →